Therapeutic Antibodies
Therapeutic Antibodies - Related Videos
09:54
Laboratory Scale Production and Purification of a Therapeutic Antibody
0 Views •
Cited by 9 •
2017
This protocol describes the production of a therapeutic antibody in a mammalian expression system. The methods described include preparation of vector DNA, stable transfection and serum-free adaptation of a human embryonic kidney 293 cell line, set up of large scale cultures and purification using affinity chromatography.
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
0 Views •
Cited by 2 •
2017
This protocol describes the in vitro comparison of two key functional characteristics of rituximab: target binding and complement-dependent cytotoxicity (CDC) induction. The methods were employed for a side-to-side comparison between reference rituximab and a rituximab biosimilar. These assays can be employed during biosimilar development or as a quality control in their production.
04:24
An Open-Source Framework for Mass Calculation of Antibody-Based Therapeutic Molecules
0 Views •
Cited by 1 •
2023
This article describes the use of a software application, mAbScale, for the calculation of masses for monoclonal antibody-based protein therapeutics.
07:36
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
0 Views •
Cited by 1 •
2020
Here we present a protocol to study the in vivo localization of antibodies in mice tumor xenograft models.
08:53
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
0 Views •
Cited by 1 •
2019
The in vivo immunofluorescence localization (IVIL) method can be used to examine in vivo biodistribution of antibodies and antibody conjugates for oncological purposes in living organisms using a combination of in vivo tumor targeting and ex vivo immunostaining methods.
FAQs
The outcome depends on what happens after antigen binding. An antibody may block a receptor or signaling protein, preventing a disease-related biological signal, or it may create a therapeutic effect through the bound molecule. It can also recruit immune mechanisms such as antibody-dependent cellular cytotoxicity, linking molecular recognition to destruction of a targeted cell.
Affinity concerns the strength of binding to the selected antigen, while stability concerns how well the engineered molecule maintains its relevant properties. Researchers examine both alongside target specificity and immune activity because these characteristics guide efforts to produce therapies that are safer and more effective. Together, they help connect antibody structure with intended biological performance.
The antigen's biological role shapes the possible therapeutic effect. Binding a cell-surface receptor can interfere with receptor-linked activity, while targeting a signaling protein can prevent a disease-related signal. Antibodies directed toward pathogen components address a different biological context. Thus, target selection links molecular recognition to the disease process researchers aim to influence.
Development and evaluation examine antibody structure, affinity, stability, target specificity, and immune activity. These properties provide different information: structure relates to molecular design, affinity to antigen recognition, stability to maintenance of relevant properties, and immune activity to recruitment of mechanisms such as antibody-dependent cellular cytotoxicity. Considering them together supports the design of safer, more effective candidates.
Researchers investigate these medicines across several disease areas, including cancer, autoimmune disorders, inflammatory diseases, and infectious conditions. The biological target and the intended antibody action differ across these settings, but each application depends on recognizing a molecule involved in disease. This broad range demonstrates how antibody-based strategies can be adapted to distinct biological problems.
Biology guides both target selection and molecule design. Researchers study disease-related antigens, antibody structure, binding affinity, stability, and immune activity to understand how a candidate may act. Those findings inform further development and evaluation, helping connect molecular features with therapeutic goals and supporting efforts to improve treatment precision, safety, and effectiveness.